Does Trimi offer retatrutide?

Trimi is actively preparing to offer compounded retatrutide as legitimate access channels develop. As of May 2026, retatrutide is not yet FDA-approved (Phase 3 TRIUMPH trials ongoing — NCT05616013, NCT05882045, NCT05882474, NCT05929066). When retatrutide becomes accessible through Trimi's 503A compounding pharmacy partners (VialsRx Texas State Board #35264 + GreenwichRx), it will be added to our treatment program at affordability-tier pricing consistent with our current $99/month compounded semaglutide and $125/month compounded tirzepatide. Trimi patients on our current GLP-1 program get priority notification when retatrutide launches.

When will Trimi offer retatrutide?

Trimi expects to add compounded retatrutide to its program once: (1) FDA classification of retatrutide on the Section 503A bulks list is clarified, (2) Eli Lilly's patent status and regulatory pathway provide compounding-pharmacy clarity, and (3) Trimi's 503A pharmacy partners can secure pharmaceutical-grade retatrutide API with appropriate USP sterility and potency verification. Patient interest is being tracked via Trimi's retatrutide waitlist. Estimated timeline: late 2026 to 2027 for compounded access, dependent on regulatory developments.

Should I start Trimi now or wait for retatrutide?

Start now. Obesity is a progressive chronic disease — delaying treatment has measurable health consequences (Endocrine Society 2024 obesity guideline). Trimi's currently available compounded semaglutide produces 14.9% mean body-weight reduction (STEP 1, NEJM 2021) and compounded tirzepatide produces 20.9% mean reduction at the 15 mg dose (SURMOUNT-1, NEJM 2022). When retatrutide becomes available at Trimi, current patients have first-priority access and clinical guidance on whether/when to transition. Patients can pause treatment between molecules with appropriate medical supervision.

Will Trimi's compounded retatrutide be the same as Eli Lilly's brand?

Trimi's compounded retatrutide (when available) will contain the same active pharmaceutical ingredient (retatrutide / LY3437943) sourced from FDA-registered API suppliers. The 503A compounding pathway produces compounded forms of FDA-approved or FDA-recognized molecules — the active ingredient is identical to Eli Lilly's brand. Difference: Trimi's compounded version is dispensed as a multi-dose vial drawn into provided syringes, while a future Eli Lilly brand would likely use pre-filled single-use pens. Both pathways are legal under federal pharmacy law (Section 503A of the FFDCA) where applicable.

Why does Trimi recommend the triple agonist?

Retatrutide is the only GLP-1 class drug that activates three incretin receptors (GLP-1 + GIP + glucagon). The glucagon-receptor component is unique among current weight-loss medications — it increases hepatic energy expenditure, fat oxidation, and basal metabolic rate beyond what GLP-1 alone (semaglutide) or GLP-1 + GIP (tirzepatide) achieve. Phase 2 data (Jastreboff et al., NEJM 2023, NCT04881760): 24.2% mean body-weight reduction at 12 mg over 48 weeks — the highest of any obesity drug to date. Trimi recommends retatrutide for patients who have plateaued on semaglutide or tirzepatide, or who need a more aggressive metabolic intervention.

What does the published clinical evidence show for retatrutide?

Peer-reviewed evidence: Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. (Source: Jastreboff et al. Phase 2 trial, NEJM 2023). Trimi is preparing for launch; compounded availability depends on FDA-cleared compounding pathways. Results vary by individual; eligibility is determined by a licensed clinician.

Retatrutide at Trimi: Where to Get the Triple Agonist (2026

Q: How do I get on the Trimi retatrutide waitlist?

Existing Trimi patients are automatically added to the priority-access list when retatrutide becomes available. Non-patients can join the waitlist by starting Trimi's current GLP-1 program (compounded semaglutide $99/month or compounded tirzepatide $125/month) — this gives clinical history, medical eligibility verification, and first-in-line access when retatrutide launches. Visit /treatments or contact care@trytrimi.com to begin.

Trimi's mission is to make the most effective weight loss treatments accessible and affordable. Retatrutide, the world's first triple agonist with up to 24.2% body weight loss in Phase 2 trials (Jastreboff et al., NEJM 2023), represents the next frontier in obesity medicine. Here is why Trimi is committed to offering this breakthrough treatment and how it fits into our comprehensive approach to weight management.

Medical Disclaimer: This article is for informational purposes only. Retatrutide is an investigational drug not yet approved by the FDA. Trimi currently offers compounded semaglutide and compounded tirzepatide as proven GLP-1 treatment options.

Why Triple Agonism Matters

Retatrutide is not just an incremental improvement over existing GLP-1 medications. It represents a paradigm shift. By activating GLP-1, GIP, and glucagon receptors simultaneously, it addresses obesity through the most comprehensive mechanism yet developed. The glucagon component adds energy expenditure and fat oxidation that single and dual agonists cannot provide. This means more weight loss, potentially better metabolic outcomes, and a new option for patients who have plateaued on other medications.

At Trimi, we believe patients deserve access to the best available treatments, not just the most marketed ones. As retatrutide becomes available, we are committed to making it accessible at affordable prices, consistent with our approach to semaglutide and tirzepatide.

The Trimi Approach

Medical-First Philosophy

Every Trimi patient receives a comprehensive medical evaluation before starting any GLP-1 medication. Our providers review medical history, current medications, contraindications, and individual goals to determine the right treatment. This personalized approach becomes even more important with retatrutide, whose triple mechanism requires understanding of metabolic, hormonal, and neurological effects.

Affordable Access

Brand-name GLP-1 medications cost $1,000-1,500+ monthly. Trimi's commitment to affordability makes treatment realistic for patients who would otherwise be priced out. Our current pricing reflects this mission:

Compounded semaglutide: $99/month
Compounded tirzepatide: $125/month
Retatrutide: Pricing to be announced when available, consistent with our affordability mission

Ongoing Medical Support

GLP-1 treatment is not just a prescription. Trimi provides dose titration guidance based on individual response, side effect management and treatment adjustment, medication interaction review, nutritional and lifestyle guidance, and regular check-ins and lab monitoring.

Current Treatment Options at Trimi

While retatrutide availability develops, Trimi offers two proven GLP-1 medications:

Compounded Semaglutide ($99/month)

The and Wegovy. Produces 15-17% average body weight loss. Extensive safety data from millions of patients. FDA-approved molecule with the longest GLP-1 track record.

Compounded Tirzepatide ($125/month)

Theand Zepbound. Dual agonist (GLP-1 + GIP) producing 22-25% weight loss. Currently the most effective FDA-approved weight loss medication. Shares two of three receptor targets with retatrutide.

Transitioning to Retatrutide

When retatrutide becomes available at Trimi, patients on semaglutide or tirzepatide will have the option to transition. Our medical team will guide the switch, including appropriate washout periods, restarting at appropriate doses, and monitoring for the unique effects of glucagon receptor activation. Starting treatment now with semaglutide or tirzepatide is the best approach: you benefit immediately and can upgrade to retatrutide when it becomes available.

Beyond Retatrutide: What's Next in GLP-1 Innovation

Retatrutide is the most advanced triple agonist, but several other next-generation obesity therapeutics are in late-stage development. Trimi is tracking each one for potential addition to the program as legitimate access pathways develop. Here's the 2026 pipeline snapshot:

Orforglipron (Eli Lilly, oral GLP-1)

Orforglipron is Eli Lilly's investigational once-daily oral GLP-1 receptor agonist (development code LY3502970). Unlike injectable semaglutide and tirzepatide, orforglipron is a small-molecule non-peptide that survives oral administration without enteric-coating requirements. Phase 3 ACHIEVE-1 trial results (NCT05869903) for type 2 diabetes were reported in April 2026, and Phase 3 ATTAIN-1 obesity trial results are expected late 2026. FDA submission for obesity expected 2027. If approved, orforglipron would be the first oral GLP-1 approved for chronic weight management — potentially expanding access for patients with needle aversion. Pricing has not been announced but is expected to follow Eli Lilly's GLP-1 tier ($1,000+ monthly retail).

CagriSema (Novo Nordisk, semaglutide + cagrilintide)

CagriSema combines semaglutide (GLP-1 agonist) with cagrilintide (amylin analog) in a single once-weekly subcutaneous injection. Phase 3 REDEFINE-1 trial results (NCT05567796) reported 20.4% mean body-weight reduction over 68 weeks in adults with obesity — comparable to high-dose tirzepatide. Novo Nordisk submitted to FDA in Q4 2025 with potential approval in 2026-2027. The dual-mechanism approach (GLP-1 appetite suppression + amylin meal-termination signaling) addresses different metabolic pathways than retatrutide's triple-receptor approach.

Survodutide (Boehringer Ingelheim + Zealand, GLP-1/glucagon)

Survodutide is a once-weekly subcutaneous dual GLP-1/glucagon receptor agonist (formerly BI 456906) developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 results reported 18.7% mean body-weight reduction at the highest dose over 46 weeks. Phase 3 SYNCHRONIZE trial program is underway (NCT06335525). Survodutide differs from retatrutide by excluding the GIP receptor — leaving GLP-1 + glucagon dual agonism. FDA submission expected 2027-2028.

Amycretin (Novo Nordisk, GLP-1 + amylin unimolecular)

Amycretin is Novo Nordisk's investigational single-molecule combining GLP-1 receptor agonism and amylin receptor activity in one compound. Phase 1b data reported 13.1% mean body-weight reduction at 12 weeks — extrapolated to ~22-25% at 68 weeks per typical GLP-1 class dose-response. Phase 2 trials launched in 2025. Earliest FDA submission expected 2028-2029. Both subcutaneous and oral formulations are in development.

Trimi's commitment: as each of these molecules progresses through regulatory pathways and (where applicable) 503A compounding becomes legitimately available, Trimi will evaluate adding them to the program. Current patients on semaglutide or tirzepatide automatically receive priority notification when any new molecule launches.

Get Started Today

Do not wait for retatrutide to begin your weight loss journey. Explore Trimi's current treatment options and start with compounded semaglutide ($99/month) or compounded tirzepatide ($125/month). Learn how Trimi works.

Frequently Asked Questions

Does Trimi currently offer retatrutide?

Trimi is actively preparing to offer retatrutide as availability expands. Currently, we offer compounded semaglutide ($99/month) and compounded tirzepatide ($125/month) as proven GLP-1 treatment options.

How much will retatrutide cost at Trimi?

Pricing will be announced when retatrutide becomes available through our pharmacy partners. Consistent with our mission, we will work to make it as affordable as possible.

Should I start semaglutide now or wait for retatrutide?

Start now. Semaglutide and tirzepatide produce excellent weight loss results, and delaying treatment allows obesity-related health risks to worsen. You can transition to retatrutide when it becomes available.

Is Trimi's compounded medication safe?

Trimi partners with accredited compounding pharmacies that follow strict quality standards. All medications are prescribed by licensed providers after medical evaluation and are manufactured from pharmaceutical-grade ingredients.

Retatrutide at Trimi: Why We Offer the Triple Agonist